Related Experiment Videos
H1-receptor antagonists. Comparative tolerability and safety
1Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Drug Safety
|May 1, 1994
Summary
Second-generation antihistamines offer improved safety over older drugs by reducing central nervous system (CNS) side effects. However, no antihistamine is entirely risk-free, necessitating careful benefit-risk assessment.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Clinical Therapeutics
Background:
- First-generation histamine H1-receptor antagonists (e.g., diphenhydramine, chlorpheniramine) are associated with significant central nervous system (CNS) adverse effects like somnolence.
- Second-generation H1-antagonists (e.g., loratadine, cetirizine) were developed to overcome the limitations of first-generation agents.
Purpose of the Study:
- To evaluate the therapeutic advance represented by second-generation H1-antagonists compared to first-generation agents.
- To assess the safety profile, including CNS and cardiovascular effects, of newer H1-antagonists.
Main Methods:
- Comparative analysis of adverse effect profiles between first- and second-generation H1-antagonists.
- Review of clinical data regarding CNS effects, interaction with alcohol, and cardiac safety.
Main Results:
- Second-generation H1-antagonists demonstrate a more favorable benefit/risk ratio at recommended doses, with reduced CNS adverse effects.
- These newer agents do not typically exacerbate CNS side effects from alcohol or other chemicals.
- Rare instances of cardiac dysrhythmias have been reported with some newer H1-antagonists, particularly after overdose.
Conclusions:
- The notion of a completely risk-free H1-antagonist is an oversimplification; no agent is free from adverse effects under all conditions.
- A comprehensive benefit-risk assessment, considering CNS and cardiovascular effects, is crucial for each H1-antagonist medication.